Recap: Immunogen Q4 Earnings

Shares of Immunogen IMGN moved higher by 2.9% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 433.33% year over year to $0.16, which beat the estimate of ($0.08).

Revenue of $85,798,000 up by 91.24% year over year, which beat the estimate of $40,830,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

The upcoming fiscal year's revenue expected to be between $65,000,000 and $75,000,000.

Details Of The Call

Date: Feb 12, 2021

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/kk8uk2b5

Technicals

Company's 52-week high was at $8.33

Company's 52-week low was at $1.95

Price action over last quarter: Up 33.82%

Company Profile

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.

Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...